The Financial Times asks an interesting question in this article today....Will the credit crunch affect M&A activity? The article discusses the possible implications of the credit crunch on Roche's bid for Genentech. While they were not mentioned specifically in the article, two other pending deals that obviously are subject to the same financial issues as the Roche/Genentech deal, are King Pharmaceuticals' bid to acquire Alpharma and the "Mystery Suitor" trying to acquire Imclone.
Time will tell if the lack of liquidity in the markets is the death knell for these deals.
Subscribe to:
Post Comments (Atom)
.jpg)
No comments:
Post a Comment